Management of Acute Pain in Patients Receiving Sublocade (Extended‑Release Buprenorphine)

General Principles

Continuing buprenorphine therapy (including extended‑release formulations such as Sublocade) while adding full mu‑opioid agonists at higher doses is recommended when analgesia is inadequate after optimizing non‑opioid therapies. Consensus statement (Mayo Clinic 2021). 1
Full opioid agonists can be safely titrated alongside buprenorphine maintenance therapy. Guideline (Annals of Internal Medicine 2006). 2
Opioid analgesics may be co‑administered with Sublocade, but doses higher than those used in opioid‑naïve patients are usually required and careful monitoring is essential. Consensus & guideline. [1][2]

Maintain Sublocade injections without interruption to avoid precipitating withdrawal and to reduce relapse risk. Consensus & guideline. [1][2]
Add short‑acting full opioid agonists (e.g., morphine, oxycodone, hydromorphone, fentanyl) at doses and dosing intervals higher than in opioid‑naïve patients—typically every 3–4 hours rather than every 4–6 hours. Guideline. 2
Use scheduled (around‑the‑clock) dosing rather than as‑needed dosing to maintain steady analgesia and prevent breakthrough pain. Guideline. 2
Avoid mixed agonist‑antagonist opioids (e.g., pentazocine, nalbuphine, butorphanol) because they can precipitate acute withdrawal. Consensus & guideline. [1][2]

Divide the Sublocade‑equivalent dose into 6–8 hour sublingual buprenorphine dosing to exploit buprenorphine’s intrinsic analgesic effect, then supplement with full agonists as needed. Guideline. 2
Temporarily discontinue buprenorphine and convert to methadone (20–40 mg daily) plus short‑acting opioids for hospitalized patients with severe acute pain; reconvert to buprenorphine before discharge, with inpatient naloxone monitoring. Guideline. 2
Discontinue buprenorphine entirely and rely on full opioid agonists alone, converting back to buprenorphine after pain resolution; this carries the highest relapse risk and should be a last‑resort option. Guideline. 2

Keep naloxone immediately available when administering full opioid agonists to patients on buprenorphine, and monitor respiratory rate and level of consciousness frequently. Guideline. 2
Notify the Sublocade prescriber or opioid‑treatment program of any additional opioid prescriptions, as they will be detected on routine urine drug screening. Guideline. 2

Under‑treating pain due to the misconception that buprenorphine blocks opioid effects; higher opioid doses can achieve adequate analgesia. Guideline. 2
Using as‑needed dosing instead of scheduled dosing, which allows pain to recur and increases patient distress. Guideline. 2
Abruptly discontinuing Sublocade to “make room” for other opioids, which precipitates withdrawal and raises overdose risk if the patient relapses to illicit opioids. Consensus & guideline. [1][2]

Addiction treatment should never be interrupted to manage pain; both can be addressed simultaneously with appropriate dosing, multimodal analgesia, and vigilant monitoring. Consensus & guideline. [1][2]

Buprenorphine has high affinity but low efficacy at mu-opioid receptors, making it a partial agonist that can block or compete with full opioid agonists like morphine 3
Buprenorphine's tight binding to mu receptors can make pain management challenging as it may reduce the effectiveness of traditional opioid analgesics 3

Continue the patient's regular Suboxone maintenance therapy while titrating a short-acting opioid analgesic (like morphine) to effect, with higher doses of morphine required to overcome buprenorphine's receptor competition 3
Split the daily Suboxone dose and administer every 6-8 hours to maximize its analgesic properties, with additional opioid analgesics like morphine potentially required for adequate pain control 3
For severe pain requiring significant opioid analgesia, discontinue Suboxone and treat with full opioid agonists like morphine, titrating to effect to prevent withdrawal and achieve analgesia 3, 4
Convert from Suboxone to methadone (30-40 mg/day) in an inpatient setting for hospitalized patients with acute pain, allowing for more predictable pain control while preventing withdrawal 4

Always have naloxone available when administering full opioid agonists to patients on buprenorphine therapy, and monitor level of consciousness and respiratory status frequently 3
Avoid mixed agonist-antagonist opioids (pentazocine, nalbuphine, butorphanol) as they can precipitate withdrawal 5
When restarting Suboxone after using full agonists, ensure the patient is in mild withdrawal before administration to prevent precipitated withdrawal 4

Monitor for signs of respiratory depression, which may occur if Suboxone is abruptly discontinued and replaced with full agonists 3
Watch for signs of withdrawal if transitioning between medications 4
Document all medications given to ensure proper coordination with the patient's Suboxone maintenance program 6